Flu drug laninamivir begins Phase III Japanese trial for prophylaxis
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has begun a Japanese Phase III trial with the long-acting neuraminidase inhibitor laninamivir (CS-8958) for the prevention of flu infections.